Press Release

<< Back
April 30, 2014 at 7:00 AM EDT

Verastem to Present at Upcoming Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 30, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that the company will participate at several upcoming conferences. The presentation details are as follows:

  • Deutsche Bank 39th Annual Healthcare Conference onWednesday, May 7, 2014 at 9:20 a.m. ET at The InterContinental Hotel in Boston, MA
  • Cancer Advance New York conference, taking place May 13-14, 2014, at Apella in New York City

A webcast of the Deutsche Bank presentation can be accessed by visiting the investors section of the Company’s website at A replay will be archived on the Verastem website for 90 days following the presentation date.

About Verastem, Inc.

Verastem, Inc. (NASDAQ:VSTM) is discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR and Wnt. For more information, please visit

Forward-looking statements:

Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.

Source: Verastem, Inc.

Verastem, Inc.
Brian Sullivan, 617-252-9314

Investor Contact

John Doyle

VP Investor Relations & Finance

Joe Rayne

Argot Partners